Why the study?
Cardiac pathological remodeling is a primary contributor to heart failure and death, but the signaling pathways that govern it are not fully elucidated.
Does homozygous KO of Fam114a1 reduce cardiac pathological remodeling in mouse models of heart failure?
Does homozygous KO of Fam114a1 reduce cardiac pathological remodeling in mouse models of heart failure?
FAM114A1 regulates Ang II signaling and promotes pathological cardiac remodeling, identifying it as a potential novel therapeutic target for heart failure.
FAM114A1 emerges as a novel remodeling regulator; hypothesis-generating for its role in human HF.
Cardiac pathological remodeling, a primary contributor to heart failure (HF) and death, is an important target for HF therapy. However, the signaling pathways that govern cardiac remodeling are not fully elucidated. Here, we found that a functionally unannotated human myocardial infarction-associated (MI-associated) gene, family with sequence similarity 114 member A1 (FAM114A1), is induced in failing human and mouse hearts compared with nonfailing hearts. Homozygous KO of Fam114a1 (Fam114a1-/-) in the mouse genome reduces cardiomyocyte hypertrophy, inflammation, and cardiac fibrosis while restoring cardiac function in angiotensin II-induced (Ang II-induced) and MI-induced HF mouse models. Cardiac fibroblasts (CFs) exhibit the highest FAM114A1 expression among different cardiac cell types. FAM114A1 is a critical autonomous factor for CF proliferation, activation, and migration. Mechanistically, FAM114A1 interacts with angiotensin receptor-associated protein (AGTRAP) and regulates the expression of angiotensin type 1 receptor (AT1R) and downstream Ang II signaling transduction, and it subsequently influences profibrotic response. Our results indicate that FAM114A1 regulates Ang II signaling, thereby activating CFs and other cardiac cells and augmenting pathological cardiac remodeling. These findings provide potentially novel insights into the regulation of cardiac remodeling and identify FAM114A1 as a therapeutic target for the treatment of heart disease.
No takes yet. Share an insight, caveat, or question.
Subbaiah et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: